Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roelf Valkema

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Clinical Imaging|May 29, 2017
Qualitative agreement and diagnostic performance of arterial spin labelling MRI and FDG PET-CT in suspected early-stage dementia: Comparison of arterial spin labelling MRI and FDG PET-CT in suspected dementiaKathleen Weyts, Meike Vernooij, Rebecca Steketee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2012
Reduction of renal uptake of radiolabeled octreotate by amifostine coadministrationMarleen Melis, Roelf Valkema, Eric P Krenning, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 6, 2003
Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002Marion de Jong, Dik Kwekkeboom, Roelf Valkema, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2003
99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy?Alida C Fröberg, Roelf Valkema, H Jaap Bonjer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2007
Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapyMark Konijnenberg, Marleen Melis, Roelf Valkema, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 25, 2014
Prediction of 14-year outcomes in patients with a limited exercise capacity: Utility of dobutamine myocardial perfusion imaging in a high-risk populationJesse F Veenis, Roelf Valkema, Ron T van Domburg, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|March 27, 2007
Neuroendocrine tumors. Peptide receptor radionuclide therapyFlavio Forrer, Roelf Valkema, Dik J Kwekkeboom, et al.
The American Journal of Cardiology|February 10, 2015
Eleven-year prognostic value of dobutamine stress (99m)Tc-sestamibi myocardial perfusion imaging in patients with limited exercise capacityHendrik J Boiten, Ron T van Domburg, Roelf Valkema, et al.
Acta Oncologica (Stockholm, Sweden)|July 27, 2007
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumoursMartijn Van Essen, Eric P Krenning, Marion De Jong, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 15, 2010
Single-photon emission computed tomography for assessment of myocardial viabilityArend F L Schinkel, Roelf Valkema, Marcel L Geleijnse, et al.
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Clinical Imaging|May 29, 2017
Qualitative agreement and diagnostic performance of arterial spin labelling MRI and FDG PET-CT in suspected early-stage dementia: Comparison of arterial spin labelling MRI and FDG PET-CT in suspected dementiaKathleen Weyts, Meike Vernooij, Rebecca Steketee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2012
Reduction of renal uptake of radiolabeled octreotate by amifostine coadministrationMarleen Melis, Roelf Valkema, Eric P Krenning, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 6, 2003
Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002Marion de Jong, Dik Kwekkeboom, Roelf Valkema, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2003
99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy?Alida C Fröberg, Roelf Valkema, H Jaap Bonjer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2007
Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapyMark Konijnenberg, Marleen Melis, Roelf Valkema, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 25, 2014
Prediction of 14-year outcomes in patients with a limited exercise capacity: Utility of dobutamine myocardial perfusion imaging in a high-risk populationJesse F Veenis, Roelf Valkema, Ron T van Domburg, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|March 27, 2007
Neuroendocrine tumors. Peptide receptor radionuclide therapyFlavio Forrer, Roelf Valkema, Dik J Kwekkeboom, et al.
The American Journal of Cardiology|February 10, 2015
Eleven-year prognostic value of dobutamine stress (99m)Tc-sestamibi myocardial perfusion imaging in patients with limited exercise capacityHendrik J Boiten, Ron T van Domburg, Roelf Valkema, et al.
Acta Oncologica (Stockholm, Sweden)|July 27, 2007
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumoursMartijn Van Essen, Eric P Krenning, Marion De Jong, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 15, 2010
Single-photon emission computed tomography for assessment of myocardial viabilityArend F L Schinkel, Roelf Valkema, Marcel L Geleijnse, et al.
Pageof 10